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Abstract
Background: Outcomes in patients with sepsis are better if initial empirical antimicrobial use is appropriate. Several
studies have shown that adherence to guidelines dictating appropriate antimicrobial use positively influences
clinical outcome, shortens length of hospital stay and contributes to the containment of antibiotic resistance.
Quality indicators (QIs) can be systematically developed from these guidelines to define and measure appropriate
antimicrobial use. We describe the development of a concise set of QIs to assess the appropriateness of
antimicrobial use in adult patients with sepsis on a general medical ward or Intensive Care Unit (ICU).
Methods: A RAND-modified, five step Delphi procedure was used. A multidisciplinary panel of 14 experts appraised
and prioritized 40 key recommendations from within the Dutch national guideline on antimicrobial use for adult
hospitalized patients with sepsis (www.swab.nl/guidelines). A procedure to select QIs relevant to clinical outcome,
antimicrobial resistance and costs was performed using two rounds of questionnaires with a face-to-face consensus
meeting between the rounds over a period of three months.
Results: The procedure resulted in the selection of a final set of five QIs, namely: obtain cultures; prescribe
empirical antimicrobial therapy according to the national guideline; start intravenous drug therapy; start
antimicrobial treatment within one hour; and streamline antimicrobial therapy.
Conclusion: This systematic, stepwise method, which combined evidence and expert opinion, led to a concise and
therefore feasible set of QIs for optimal antimicrobial use in hospitalized adult patients with sepsis. The next step
will entail subjecting these quality indicators to an applicability test for their clinimetric properties and ultimately,
using these QIs in quality-improvement projects. This information is crucial for antimicrobial stewardship teams to
help set priorities and to focus improvement.
Keywords: Sepsis, Antimicrobial treatment, Quality indicator, Quality improvement, Appropriate antimicrobial use,
Appropriate antibiotic use
Background
Severe sepsis and septic shock are a substantial burden
to health care, affecting millions of patients around the
world each year [1]. The average cost of care for a
patient with severe sepsis is about 22.000 USD [2]. It is
often thought that severe sepsis is primarily seen on the
intensive care unit (ICU). However, studies point out
that the majority (50 – 68%) of patients with severe
sepsis are admitted to a general medical ward [3], with a
mortality rate around 26 – 29.5% [4,5]. Since the diagnosis
‘severe sepsis’ is often poorly documented in the medical
records by the treating clinicians, specific sepsis-targeted
measures may not have been performed and antimicrobial
use may have been inappropriate [3].
As the necessary first step in the improvement of
appropriate use in patients with sepsis, guidelines have
been developed that describe appropriate antimicrobial
use in patients with sepsis admitted to a general medical
ward or an Intensive Care Unit (ICU). Despite the avail-
ability of these guidelines, antimicrobials are used inappro-
priately: several studies show that inappropriate initial
antimicrobial use in patients with severe sepsis or septic
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shock is associated with a reduction in survival [6-9]. As a
second important step towards change and improvement
of daily clinical care, the guideline-based development
of quality indicators has been suggested [10,11]. Quality
indicators (QIs) are measurable elements that can be
used to gain insight into the appropriateness of the
given antimicrobial treatment, which is important to set
priorities and to focus improvement. The aim of our
study was to develop a concise and therefore feasible set
of QIs to measure and monitor the appropriateness of
antimicrobial use in adults with sepsis admitted to a
general medical ward and/or ICU.
Methods
Delphi survey
The Dutch Working Party on Antibiotic Policy (SWAB)
publishes evidence-based guidelines for antimicrobial use.
We used the guideline for antimicrobial use in hospital-
ized patients with sepsis (published online in 2010) as a
starting point for the development of a set of QIs [12].
This guideline covers antimicrobial use in all hospitalized
adult patients with sepsis, except antimicrobial use in sep-
sis associated with indwelling intravascular devices that
are not removed (tunnelled catheter or totally implantable
vascular access devices) and therefore requires different
therapy.
We used a systematic approach -the RAND-modified
Delphi method [13,14]- to develop a set of QIs in order
to measure the appropriateness of antimicrobial treat-
ment in adult patients with sepsis admitted to a general
ward and/or ICU (Figure 1). For developing QIs by
means of the Delphi method medical ethical approval
was not required.
Extraction of guideline recommendations
One infectious diseases physician and one quality-of-
care specialist independently extracted key recommen-
dations from the national guideline for antimicrobial use
in hospitalized patients with sepsis. Disagreements were
resolved by consensus. The selected recommendations
were translated into potential QIs and each indicator was
graded to determine its scientific soundness (level of
evidence), using Tables 1 and 2 [15].
First questionnaire round
The list of the potentially relevant QIs was converted into
a written questionnaire and used for the RAND-modified
Delphi method to achieve expert consensus on these
QIs. The consensus procedure was performed between
February and April 2011. All authors of the above men-
tioned national guideline, and an additional intensive care
specialist and a hospital pharmacist were approached, and
they all agreed to participate in the multidisciplinary
expert panel. Our final expert panel consisted of four
infectious diseases physicians (all working primarily outside
the ICU), two medical microbiologists, two hospital phar-
macists, three intensive care specialists, two haematologists
and one general surgeon (14 experts).
The questionnaire was sent by email to the experts,
asking them to rate the QIs using the following criteria:
 The potential QI leads to health gain for the patient,
less bacterial resistance or promotes efficiency of
care;
 The potential QI is generalizable to all adult patients
treated for sepsis with antimicrobial use;
 There is enough scientific evidence or expert
consensus to justify the recommended care.
The expert panel was asked to rate the potential QIs
using a 9-point Likert scale (with 1 denoting “definitely
Step 3: expert panel meeting (start n = 32):
13 accepted, 2 rephrased, 17 were ‘rejected’ and 
mergedd into 4 new composite QIs, 
1 new potential QIs was addede
Step 4: second questionnaire (start n = 20):
ranking procedure to prioritize 
6 QIs received the most points (2 QIs were merged into 
1 QI after comments from the experts)
Step 5: Final set of 5 potential QIs
Step 2: first questionnaire round (start n = 40):
22 accepteda,
9 discussionb, 1 new proposed potential QI
Step 1: Extraction of key recommendations from the 
national SWAB guideline for antimicrobial therapy of 
hospitalized adult patients with sepsis. n = 40
Rejected
n = 14
Rejectedc
n = 9
n = 40 potential QIs:
n = 25 QIs on empirical therapy
n = 9 QIs on modifying antimicrobial therapy/dose
n = 3 QIs on monitoring antimicrobial therapy
n = 2 QIs when to stop antimicrobial therapy
n = 1 QI on iv-oral switching
Figure 1 The step-wise RAND-modified Delphi method. a.
Accepted: the potential QI was selected for the next round because of
an overall median score of 8 or 9, without disagreement. Disagreement
was defined as the case in which less than 70% of the scores were in
the top tertile (scores 7, 8, or 9). b. Discussion: the QI had a median
score of 7 without disagreement or a median score of 8 or 9 with
disagreement, and so it was discussed during the consensus meeting.
c. Rejected: disagreement between panel members and the median
was also lower than 8; the potential indicator was deselected and not
discussed during the consensus meeting. d. Merged: multiple
indicators were ‘rejected’ and merged into a composite, more generic
indicator. e. Added: the indicator was proposed by one of the experts
and was added to the initial set of indicators.
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not appropriate care” and 9 denoting “definitely appro-
priate care”). The answer category ‘cannot assess’ was
also available. The panel members (experts) were asked
to add suggestions and comments regarding the poten-
tial QIs, and also to add additional potential QIs or
topics for consideration.
The results from the first questionnaire were analysed
using a standardized Microsoft Office Access-based con-
sensus tool. Potential QIs rated with an overall median
score of 8 or 9 without disagreement were considered to
be face valid and reliable [16], and were accepted as pre-
liminary indicators. Disagreement was defined as the case
in which less than 70% of the scores were in the top tertile
(scores 7, 8, or 9) [16]. If there was disagreement and the
median score was below 8, the potential indicator was
rejected and not discussed during the consensus meeting.
QIs with a median score of 7 without disagreement or a
median score of 8 or 9 with disagreement were discussed
during the consensus meeting.
Expert panel meeting
All panel members were invited for a consensus meet-
ing during which an overview of the first round ratings
was provided. Goals of the consensus meeting were to
achieve consensus on the QIs with a median score of 7
without disagreement or a median score of 8 or 9 with
disagreement, and to rephrase accepted indicators using
the comments from the panel in the first round of ques-
tionnaires. These QIs and the suggested new QIs by the
panel members were discussed and reformulated when
necessary.
Second questionnaire round, ranking procedure
After the consensus meeting, all discussed, reformulated
and added potential indicators were included in a second
questionnaire. First, the panel was asked whether they
agreed (yes or no) with the proposed indicators and their
definitions. Redefined indicators were accepted if at least
70% of the experts agreed with the new formulation.
Second, the panel was asked to prioritize the potential
indicators by selecting the ‘top 5’ of most important in-
dicators. For each number-one ranking by a panel mem-
ber, we granted a potential QI five points, for each
number-two ranking, we granted four points and so on.
QIs receiving more than 15% of the maximum possible
ranking points were considered to be the most relevant
indicators.
Results
Extraction of guideline recommendations
Key recommendations were extracted from the national
guideline independently by one infectious diseases phys-
ician (S.E.G.) and one quality-of-care specialist (M.E.L.J.H.).
In consensus, 40 key recommendations were extracted
from the national guideline and translated into potential
QIs.
Figure 1 shows the entire Delphi method as performed
in the next steps.
First questionnaire round
The 40 potential QIs were scored by 12 of the 14 panel
members during the first questionnaire round (86% re-
sponse rate). Twenty-two potential QIs had a high score
(8 or 9) without disagreement and were accepted, and
nine potential indicators were rejected, see Figure 1 and
Table 3. The panel did not agree on nine potential QIs,
they either had a median score of 7 without disagreement
or a median score of 8 or 9 with disagreement. One new
potential indicator regarding adapting the antimicrobial
dose to renal function was proposed by one panel mem-
ber. Results are shown in Table 3.
Expert panel meeting
Six panel members (four infectious diseases specialists,
one medical microbiologist and one intensive care special-
ist) were present during the consensus meeting (43%).
The 22 accepted QIs with comments from the panel, the
Table 1 Grading system for methodological quality of individual studies [15]
Intervention Aetiology, prognosis
A1 Systematic review of at least two independent A2-level studies
A2 Randomised Controlled Trial (RCT) of sufficient methodological quality
and power
Prospective cohort study with sufficient power and with adequate
confounding corrections
B Comparative Study lacking the same quality as mentioned at A2
(including patient-control and cohort studies)
Prospective cohort study lacking the same quality as mentioned at A2,
retrospective cohort study or patient-control study
C Non-comparative study
D Expert opinion
Table 2 Level of evidence of conclusions
Conclusions based on
1 Study of level A1 or at least two independent studies of level A2
2 One study of level A2 or at least two independent studies of level B
3 One study of level B or C
4 Expert opinion
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Table 3 Results Delphi procedure: first questionnaire, consensus meeting and second questionnaire
Quality indicators Level of supporting
evidence (see Table 2)
First questionnaire Consensus
meeting
Second questionnaire
Median
score
% in highest
tertile
Conclusion Nr of experts
prioritizing
the QI
Total
score
Conclusion
1. Start antimicrobial therapy intravenously in adult patients with sepsis 4 9 92 Accepteda Accepted 7 26 Accepted
2. Start antimicrobial therapy as soon as possible, preferably within the first
hour in adult patients with severe sepsis and septic shock
2 9 100 Accepted Accepted 12 50 Accepted
3. Before starting antimicrobial therapy, at least two sets of blood cultures, and
specimens for culture from suspected sites of infection should be taken.
4 9 100 Accepted Accepted 9 36 Accepted
4. For community-acquired sepsis without neutropenia and without an
obvious site of infection, start a second or third generation cephalosporin,
or amoxicillin and clavulanic acid + an aminoglycoside. Duration of therapy:
7–10 days.
* 8 92 Accepted Mergedd
into number
43/44
5. For nosocomial sepsis without neutropenia and with no obvious site of
infection, start piperacillin with tazobactam, or a second or third
generation cephalosporin (except ceftazidime) in combination with either
an aminoglycoside or an anti-pseudomonal fluoroquinolone. Duration of
therapy: 7–10 days.
* 7 75 Discussionb Merged into
number
43/44
6. For community-acquired or nosocomial sepsis with neutropenia and
without an obvious site of infection, start piperacillin and tazobactam +/−
an aminoglycoside or a carbapenem with anti-pseudomonal activity
(imipenem/meropenem) as empirical antibacterial regimen. Duration of
therapy: 7–10 days.
* 7 75 Discussion Merged into
number
43/44
7. The addition of an aminoglycoside to a beta-lactam agent in adult patients
with sepsis is not recommended, unless based on local resistance data and
epidemiology (e.g. risk factors for ESBL) a broad spectrum of empirical
therapy against Gram-negative pathogens is needed.
* 8 75 Accepted Accepted 3 6 Rejected
8. Glycopeptides should generally not be part of the empirical antibacterial
regimen in adults with sepsis (with or without neutropenia), unless patients
are known to be colonised with MRSA, or in patients with severe sepsis and
neutropenia who received penicillin or cephalosporin prophylaxis.
* 8 83 Accepted Accepted 0 0 Rejected
9. For community-acquired and nosocomial sepsis and prior use of
cephalosporins or quinolones within 30 days before presentation, an
aminoglycoside should be added or a carbapenem with antipseudomonal
activity should be started. This also accounts for adults colonised with
ESBL-producing micro-organisms and for those admitted to a hospital with
high prevalence of ESBL-producing Enterobacteriaceae. If prevalence is
unknown, risk factors for ESBL should be used. Risk factors are: a
nosocomial infection, prior use of antibiotics and presence of an indwelling
urinary catheter.
2 8 92 Accepted Accepted 2 4 Rejected
10. Empirical antifungal therapy may be considered in selected cases:
unexplained sepsis with long-term ICU stay, significant Candida
colonisation, and clinical risk factors such as abdominal surgery,
anastomosis leakage, the presence of a central venous catheter and the
use of broad spectrum antibiotics.
* 8 73 Accepted Merged into
number
43/44
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Table 3 Results Delphi procedure: first questionnaire, consensus meeting and second questionnaire (Continued)
11. For sepsis with a hospital-acquired pneumonia or a ventilated-acquired
pneumonia, start amoxicillin and clavulanic acid + an aminoglycoside or
ciprofloxacin, or the combination of a second/third generation
cephalosporin (excluding ceftazidime) with an aminoglycoside or
ciprofloxacin or start piperacillin with tazobactam. Duration of therapy:
maximum of 8 days.
1 7 67 Rejectedc
12. For urosepsis, start a second/third generation cephalosporin or the
combination of amoxicillin and gentamicin as empirical antibacterial
regimen. Duration of therapy: 10 days.
* 7 92 Discussion Merged into
number
43/44
13. For urosepsis and an indwelling urinary catheter, start a second/third
generation cephalosporin + an aminoglycoside or quinolone as empirical
antibacterial regimen.
* 7 67 Rejected
14. In adults with urosepsis, glycopeptides should be restricted to those
septic patients with previously bacteriologically proven Enterococcus
faecium urinary tract infections in which enterococci are suspected to be
the causative pathogens.
* 8 83 Accepted Merged into
number 43d
15. For community-acquired intra-abdominal sepsis, start a second/third
generation cephalosporin + metronidazole +/− an aminoglycoside or
amoxicillin and clavulanic acid +/− an aminoglycoside. Duration of
therapy: 5–7 days.
2 8 92 Accepted Merged into
number
43/44
16. For nosocomial intra-abdominal sepsis, start a second/third generation
cephalosporin + metronidazole + an aminoglycoside or amoxicillin and
clavulanic acid + an aminoglycoside or piperacillin with tazobactam +/−
an aminoglycoside. Duration of therapy: 5–7 days.
2 7 75 Discussion Merged into
number
43/44
17. For community-acquired sepsis with cholangitis, start amoxicillin + an
aminoglycoside or amoxicillin and clavulanic acid +/− an aminoglycoside.
Duration of therapy: up to 3 days following adequate drainage.
* 7 83 Discussion Merged into
number
43/44
18. For nosocomial sepsis with cholangitis, start amoxicillin (with or without
clavulanic acid) + an aminoglycoside. Duration of therapy: up to 3 days
following adequate drainage.
* 7 75 Discussion Merged into
number
43/44
19. For uncomplicated skin and skin structure infections (SSSI) with sepsis,
start flucloxacillin.
2 8 82 Accepted Merged into
number 43
20. For community acquired complicated SSSI with sepsis, start amoxicillin
and clavulanic acid. Duration of therapy: 7–10 days.
* 8 67 Discussion Merged into
number
43/44
21. For nosocomial complicated SSSI with sepsis, start amoxicillin and
clavulanic acid + an aminoglycoside or piperacillin with tazobactam.
Duration of therapy: 7–10 days.
* 8 75 Accepted Merged into
number
43/44
22. For community-acquired sepsis and necrotising fasciitis, start amoxicillin
and clavulanic acid + clindamycin.
* 6 50 Rejected
23. For nosocomial sepsis and necrotising fasciitis, start amoxicillin and
clavulanic acid + an aminoglycoside + clindamycin or piperacilllin with
tazobactam +/− an aminoglycoside + clindamycin.
* 7 67 Rejected
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Table 3 Results Delphi procedure: first questionnaire, consensus meeting and second questionnaire (Continued)
24. Cephalosporins (+/−metronidazole) are suitable alternatives in patients
with non-IgE mediated penicillin rash.
* 7 67 Rejected
25. In type I IgE allergic reactions to penicillins, aztreonam or
ciprofloxacin +/− an aminoglycoside in combination with vancomycin
should be chosen.
* 6 45 Rejected
26. Individualization of dosing using therapeutic drug monitoring should be
used whenever possible in adults with sepsis. For aminoglycosides after
3 days and for vancomycin after 5 days.
3 6 50 Rejected
27. When starting vancomycin therapy, at least one trough concentration
(just before the fourth dose) should be determined and the
concentration should be 15-20 mg/l.
3 7 50 Rejected
28. Frequent measuring of vancomycin trough concentrations is
recommended in patients with an increased risk of toxicity or unstable
kidney function and > 5 days of treatment.
3 8 75 Accepted Rephrased to
number 47
29. With proven Pseudomonas bacteraemia, combination therapy should not
be prescribed. Duration of therapy is 7 – 10 days.
2 7 70 Discussion Merged into
number
44/45
30. For sepsis due to methicillin susceptible Staphylococcus aureus, start
flucloxacillin.
2 8 100 Accepted Accepted 1 3 Rejected
31. Micro-organisms with MICs > 1 mg/l such as Pseudomonas aeruginosa or
patients with neutropenia should have an intravenous ciprofloxacin
dosage of 400 mg tid.
4 8 100 Accepted Accepted 0 0 Rejected
32. Treatment duration should be 14 days for sepsis and pneumonia due to
S. aureus.
4 9 89 Accepted Merged into
number 44
33. Treatment duration should be 14–21 days for sepsis and pneumonia due
to Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia spp.
4 8 90 Accepted Merged into
number 44
34. Treatment duration should be 14 days in an uncomplicated
Staphylococcus aureus bacteraemia.
4 9 91 Accepted Merged into
number 44
35. With S. aureus bacteraemia it is important to search for complications, this
will determine the duration of therapy. Complications are: a secondary
infection together with the S. aureus bacteraemia (like an endocarditis,
infected prosthesis, arthritis, osteomyelitis, meningitis, fasciitis, spleen
abscess)
4 8 67 Discussion Accepted 1 2 Rejected
36. Persistence of positive blood cultures for more than 72 hours after
starting antibiotics should be considered as complicated S. aureus
bacteraemia.
4 8 75 Accepted Accepted 1 1 Rejected
37. With sepsis and Listeriosis, the duration of therapy should be 21 days. 4 7 67 Rejected
38. After clinical recovery and when the identity and susceptibility of the
causative micro-organism has been determined, a switch to oral agents
with high bioavailability should be made.
2 8 91 Accepted Rephrased to
number 48
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Table 3 Results Delphi procedure: first questionnaire, consensus meeting and second questionnaire (Continued)
39. Empirical antimicrobial therapy for presumed sepsis should be
discontinued in case of clinical improvement and a lack of
clinical and microbiological evidence of infection. Maximum
duration of therapy is 7 days.
4 8 83 Accepted Accepted 2 5 Rejected
40. Discontinue broad spectrum antimicrobial therapy after
72 hours of clinical stability in patients with persisting
febrile neutropenia that show no clinical or microbiological
evidence of infection. Oral antimicrobial prophylaxis against
Gram-negative micro-organisms should be continued until
resolution of neutropenia.
2 9 91 Accepted Accepted 2 2 Rejected
QIs added after first questionnaire:
41. When starting treatment in adults with sepsis, dose and
dosing interval of systemic antimicrobial therapy should
be adapted to renal function.
4 Addede Accepted 3 4 Rejected
42. Concerning empirical therapy for adult patients with
sepsis, local guidelines should correspond to the national
guideline, but should deviate based on local resistance patterns.
4 Added 9 27 Accepted and
merged with
number 43
43. Empirical antimicrobial therapy (only choice of antimicrobial
agent) in all adult patients with sepsis should be prescribed
according to the national guideline.
* Added 2 7 Accepted and
merged with
number 42
44. In all adult patients with sepsis starting antimicrobial therapy the duration
of therapy should be prescribed according to the national guideline.
4 Added 3 4 Rejected
45. Change empirical antimicrobial therapy to pathogen-directed therapy if
culture results become available.
3 Added 7 15 Accepted
46. Patients with a S. aureus bacteraemia should have a blood culture taken
48 – 72 hours after starting empirical antibiotic therapy.
4 Added 0 0 Rejected
47. Therapeutic drug monitoring should be done if vancomycin or
aminoglycosides are given > 48 hours, according to the local guideline.
The vancomycin trough concentration should be 15-20 mg/l.
Result from
rephrasing
number 28
1 1 Rejected
48. After clinical recovery and when the identity and susceptibility of the
causative micro-organism has been determined, a switch to oral agents
with high bioavailability should be made. Exceptions are: S. aureus
bacteraemia, liver abscess, empyema, endocarditis, meningitis and
infected prosthetic material.
Result from
rephrasing
number 38
1 1 Rejected
*Based on available Dutch epidemiology and resistance data. aAccepted: the potential QI was selected for the next round because of an overall median score of 8 or 9, without disagreement. Disagreement was
defined as the case in which less than 70% of the scores were in the top tertile (scores 7, 8, or 9). bDiscussion: the QI had a median score of 7 without disagreement or a median score of 8 or 9 with disagreement, and
so it was discussed during the consensus meeting. cRejected: disagreement between panel members and the median was also lower than 8; the potential indicator was deselected and not discussed during the
consensus meeting. dMerged: multiple indicators were ‘rejected’ and merged into a composite, more generic indicator. eAdded: the indicator was proposed by one of the experts and was added to the initial set
of indicators.
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nine potential QIs with disagreement and the new indica-
tor were discussed during the meeting.
From these 32 QIs, this smaller panel accepted 13 po-
tential QIs; two QIs were rephrased and one new potential
QI was added. The other 17 QIs were rejected and merged
into four new composite QIs. These potential QIs had a
more generic formulation and contained: starting empir-
ical antimicrobial therapy; duration of therapy; changing
empirical therapy to pathogen-directed therapy; and
harmonizing local guidelines with the national guideline
(indicator 42 – 45, Table 3). This resulted in a total set
of 20 potential QIs.
Second questionnaire round, ranking procedure
After the consensus meeting, the resulting 20 potential
indicators were sent to the entire panel for comments
and approval. This questionnaire was scored by 13 of
the 14 panel members (93% response rate). All 20 indi-
cators were accepted, because in all cases 70% or more
of the panel members agreed with the new content and
rephrasing. Indicator 42 and 43 (local guidelines should
correspond to the national guideline and prescribe ac-
cording to the national guideline) were merged into one
indicator because four out of the 13 panel members
(31%) found them to be overlapping indicators. In the
same questionnaire the panel members were also asked
to rank the QIs. Out of this set of 19 indicators, five indi-
cators received more than 15% of the maximum possible
ranking points and were prioritized. They were found to
be the most important QIs for antimicrobial care in adult
patients with sepsis. The results of the second question-
naire are shown in Table 3 and Table 4 shows the final
set of QIs. For the attendance list of the participation of
the Delphi procedure and the development of the sepsis
guideline, see Additional file 1: Table S1.
Discussion
This systematic, stepwise method combining evidence and
expert opinion, generated a valid, concise and therefore
feasible set of five QIs to measure appropriate antimicro-
bial use in adult patients with sepsis admitted to general
medical wards and/or ICUs. One QI specifically applies
to patients with severe sepsis or septic shock (Table 4,
indicator 2).
The issue of local resistance patterns and national versus
local guideline recommendations for empirical treatment
choices was extensively discussed during the Delphi con-
sensus meeting. The national sepsis guideline underlines
that hospitals can and should deviate from the recommen-
dations based on local resistance patterns. We therefore
favored to follow the national guidelines, but to guarantee
the generalizability of the QIs another QI was added
Table 4 Final set of quality indicators to monitor antimicrobial use in hospitalized adult patients with sepsis
Indicator
number from
Table 3
Quality indicator Numerator description Denominator description
All patients are: hospitalized adult
patients with sepsis, severe sepsis or
septic shock, where systemic
antimicrobial therapy must be started
All patients are: hospitalized adult
patients with sepsis, severe sepsis or
septic shock, where systemic
antimicrobial therapy must be started
All patients are: hospitalized adult
patients with sepsis, severe sepsis or
septic shock, where systemic
antimicrobial therapy must be started
Number 1. Antimicrobial therapy in adult patients
with sepsis should be started
intravenously.
Number of patients who started with
empirical systemic antimicrobial therapy
intravenously.
Total number of patients who started
with empirical systemic antimicrobial
therapy.
Number 2. Antimicrobial therapy should be started as
soon as possible, preferably within the first
hour in adult patients with severe sepsis
and septic shock.
Number of patients with severe sepsis or
septic shock who started with empirical
systemic antimicrobial therapy within the
first hour after the clinical diagnosis.
Total number of patients with severe
sepsis or septic shock, who started with
empirical systemic antimicrobial therapy.
Number 3. Before starting antimicrobial therapy, at
least two sets of blood cultures and
specimens for culture from suspected sites
of infection should be taken.
Number of patients from whom at least 2
blood cultures and specimens for culture
from suspected sites of infection were
taken before empirical systemic
antimicrobial therapy was started.
Total number of patients who started
with empirical systemic antimicrobial
therapy.
Number 45. Empiric systemic antimicrobial therapy
should be changed to pathogen-directed
therapy if culture results become available.
Number of patients with a positive culture
and empirical systemic antimicrobial
therapy, which was changed to pathogen-
directed therapy after the results became
available.
Total number of patients with empirical
systemic antimicrobial therapy whose
culture became positive.
Number 43
and number 42.
Empiric systemic antimicrobial therapy
(only choice of antimicrobial agent) should
be prescribed according to the national
guideline. The local guidelines should
correspond to the national guideline, but
should deviate based on local resistance
patterns.
Number of patients who started with
empirical systemic antimicrobial therapy
according to the national guideline.
Total number of patients who started
with empirical systemic antimicrobial
therapy (only choice of antimicrobial
agent).
Number of hospitals with a local guideline
that corresponds with the national
guideline or only deviates based on local
resistance patterns.
Total number of hospitals with a local
guideline.
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during the consensus meeting; local guidelines should
correspond to the national guideline, but should deviate
based on local resistance patterns (QI number 42).
In a systematic review performed by McGregor et al.
empiric or definitive antibiotic therapy was considered to
be appropriate if the regimen exhibited in vitro activity
against the isolated pathogen(s) [17]. We derived our key
recommendations for appropriate antibiotic therapy from
the national, evidence-based guideline for antimicrobial
use in hospitalized patients with sepsis. This, according to
the national and international experts, implies more than
correct (empirical or definitive) antibiotic therapy alone:
it defines correct antimicrobial use at patient level along
the entire antibiotic pathway, from start (including ap-
propriate diagnostics) to streamlining and discontinuing
of antimicrobial therapy.
The final set consists of independent QIs, that can be
used to provide insight into the appropriateness of current
antimicrobial use, to identify where there is room for im-
provement [18]. In a recent paper by our group [19] we
found that patients with urinary tract infections who in
particular adherence to the total set of QIs, showed a sig-
nificant dose–response relationship with a shorter length
of hospital stay. This argues for application of the QIs in a
bundle approach.
This is the first study that specifically describes the de-
velopment of QIs for the entire antimicrobial treatment
of sepsis patients, also outside the ICU, via the modified
Delphi technique. Several studies have described the use
of quality measures for antimicrobial sepsis treatment
[20-25]. However, some indicators were not systematically
developed using a Delphi method [21], and some only
focused on optimal sepsis care on the ICU [20,24] or
focused on the start of treatment (first 24 hours) and
not on the entire clinical course [22,23,25].
The results of our study show resemblance with the
concise Surviving Sepsis Campaign Care Bundle origi-
nated from the guideline [1,26]. They also defined the
optimal start of antimicrobial treatment and taking cul-
tures as important parameters, only our panel members
also defined streamlining as an important QI.
Our study has several strengths. We used the systematic
modified Delphi method, a common and validated tech-
nique in which scientific evidence is combined with expert
opinion [13,14,27,28]. Boulkedid and colleagues recently
reviewed its use and reporting, and formulated a practical
guideline for using this RAND modified Delphi technique.
Our procedure is consistent with their guideline [29]. Our
panel was multidisciplinary, with 14 experts from 6 differ-
ent specialties. Furthermore, the response rate of the first
and second questionnaire (86% and 93%) was high, which
increases the validity of the results.
A limitation of this study is the national setting in
which the QIs were developed, with a Dutch national
expert panel and a Dutch guideline. This leads to the
question of whether the results can be generalized to a
wider international population. However, the guideline
reviewed and graded the recent international literature
and the QI development was performed by a multidiscip-
linary panel, in which several members have international
experience and expertise on the topic.
Another potential limitation was the attendance at the
expert panel meeting, which was 43%. However an exten-
sive summary concerning the results from the consensus
meeting was sent to all panel members, as they were asked
to give their final remarks and approval for the added and
rephrased potential QIs. Since 93% returned the second
questionnaire, we believe that an incomplete attendance
did not undermine the validity of the results.
Conclusion
We describe the complete and precise development of a
concise set of quality indicators for optimal antimicrobial
use in hospitalized adult sepsis patients, by means of the
Delphi method. This paper can be used as manual for
others, since transparency of healthcare becomes more
important worldwide, and QIs give insight into the appro-
priateness of daily clinical care. At this moment, we are
testing the applicability of this set of QIs in practice in 22
hospitals. After establishing their clinimetric properties we
will analyze the association between adherence to the QIs
and outcomes like duration of hospital stay. In the future,
our guideline-based indicators can be used for national
monitoring of antimicrobial use in hospitalized adults with
sepsis or for quality improvement projects. This informa-
tion is crucial for antimicrobial stewardship teams to help
set priorities and to focus improvement.
Additional file
Additional file 1: Table S1. Participation Delphi procedure and
development Sepsis guideline.
Abbreviations
QIs: Quality indicators; SWAB: Dutch working party on antibiotic policy;
ICU: Intensive care unit; USD: United States dollar.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CB conducted and organized the entire Delphi procedure, analyzed the
results, prepared the consensus meeting and drafted the manuscript. MH
carried out the extraction of the guideline recommendations, participated in
organizing the Delphi procedure and analyzing the results, and rewrote/
revised the manuscript. SN participated in the Delphi procedure and
rewrote/revised the manuscript. IG participated in the Delphi procedure and
rewrote/revised the manuscript. JP participated in the consensus meeting,
helped organizing the Delphi procedure and rewrote/revised the
manuscript. SE carried out the extraction of the guideline recommendations,
participated in organizing the Delphi procedure and analyzing the results,
and rewrote/revised the manuscript. All authors read and approved the final
manuscript.
van den Bosch et al. BMC Infectious Diseases 2014, 14:345 Page 9 of 10
http://www.biomedcentral.com/1471-2334/14/345
Acknowledgments
Collaborators: Dutch Sepsis QI expert panel. H.I. Bax, MD. E.F. Schippers, MD,
PhD. S. van Assen, MD, PhD. C.W. Ang, MD, PhD. P. Sturm, MD, PhD. Y.G. van
der Meer, PhD. Prof. M.A. Boermeester, MD. J.A. Schouten, MD, PhD. Prof. P.
Pickkers, MD. J.J.W.M. Janssen, MD, PhD. Prof. N.M.A. Blijlevens, MD. N.P.
Juffermans, MD, PhD.
Funds
This work was supported by Zon/MW, the Netherlands Organisation for
Health Research and Development, project number 205100003.
Author details
1Department of Internal Medicine, division of Infectious Diseases, Center for
Infection and Immunity Amsterdam (CINIMA) Academic Medical Center,
Meibergdreef 9, 1105, AZ, Amsterdam Zuidoost, The Netherlands. 2Scientific
Institute for Quality of Healthcare (IQ healthcare), Radboud University
Medical Center, Nijmegen, The Netherlands. 3Department of Clinical
Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
4Department of Internal Medicine, Radboud University Medical Center,
Nijmegen, The Netherlands. 5Department of Medical Microbiology and
Infectious Diseases, Canisius Wilhelmina Ziekenhuis, Nijmegen, The
Netherlands. 6Hasselt University, Hasselt, Belgium.
Received: 28 November 2013 Accepted: 9 June 2014
Published: 20 June 2014
References
1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky
JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend
SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR,
Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis
Campaign Guidelines Committee including the Pediatric Subgroup:
Surviving sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580–637.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR:
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med 2001, 29:1303–1310.
3. Rohde JM, Odden AJ, Bonham C, Kuhn L, Malani PN, Chen LM, Flanders SA,
Iwashyna TJ: The epidemiology of acute organ system dysfunction from
severe sepsis outside of the intensive care unit. J Hosp Med 2013,
8:243–247.
4. Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F,
Honrubia T, Algora A, Bustos A, Garcia G, Diaz-Regañón IR, de Luna RR:
Sepsis incidence and outcome: contrasting the intensive care unit with
the hospital ward. Crit Care Med 2007, 35:1284–1289.
5. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K:
Epidemiology of sepsis in Victoria, Australia. Crit Care Med 2005, 33:71–80.
6. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-
Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical
antibiotic therapy on the outcome of patients admitted to the intensive
care unit with sepsis. Crit Care Med 2003, 31:2742–2751.
7. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial
treatment of infections: a risk factor for hospital mortality among
critically ill patients. Chest 1999, 115:462–474.
8. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G,
Kumar A, Simon D, Peters C, Ahsan M, Chateau D, Cooperative
Antimicrobial Therapy of Septic Shock Database Research Group: Initiation
of inappropriate antimicrobial therapy results in a fivefold reduction of
survival in human septic shock. Chest 2009, 136:1237–1248.
9. Menendez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, Borderias
L, Martin-Villasclaras JJ, Bello S, Alfageme I, de Castro FR, Rello J, Molinos L,
Ruiz-Manzano J: Initial management of pneumonia and sepsis: factors
associated with improved outcome. Eur Respir J 2012, 39:156–162.
10. Grol R, Grimshaw J: From best evidence to best practice: effective
implementation of change in patients' care. Lancet 2003, 362:1225–1230.
11. Campbell SM, Braspenning J, Hutchinson A, Marshall MN: Research
methods used in developing and applying quality indicators in primary
care. BMJ 2003, 326:816–819.
12. SWAB guidelines for Antibacterial therapy of adult patients with sepsis.
2010. http://www.swab.nl/swab/cms3.nsf/uploads/65FB380648516FF2C
125780F002C39E2/$FILE/swab_sepsis_guideline_december_2010.pdf.
13. Mourad SM, Hermens RP, Nelen WL, Braat DD, Grol RP, Kremer JA:
Guideline-based development of quality indicators for subfertility care.
Hum Reprod 2007, 22:2665–2672.
14. Stienen JJ, Tabbers MM, Benninga MA, Harmsen M, Ouwens MM:
Development of quality indicators based on a multidisciplinary,
evidence-based guideline on pediatric constipation. Eur J Pediatr 2011,
170(12):1513–1519.
15. CBO: Kwaliteitsinstituut voor de Gezondheidszorg CBO, handleiding voor
werkgroepleden. [http://www.cbo.nl/themas/evidence-based-werken-
richtlijnen-/projecten/richtlijnen]
16. Campbell SM, Cantrill JA, Roberts D: Prescribing indicators for UK general
practice: Delphi consultation study. BMJ 2000, 321:425–428.
17. McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP Jr, Miller
RR, Furuno JP: A systematic review of the methods used to assess the
association between appropriate antibiotic therapy and mortality in
bacteremic patients. Clin Infect Dis 2007, 45:329–337.
18. Marwick C, Watts E, Evans J, Davey P: Quality of care in sepsis
management: development and testing of measures for improvement.
J Antimicrob Chemother 2007, 60:694–697.
19. Spoorenberg V, Hulscher ME, Akkermans RP, Prins JM, Geerlings SE:
Appropriate antibiotic use for patients with urinary tract infections
reduces length of hospital stay. Clin Infect Dis 2014, 58:164–169.
20. Berenholtz SM, Pronovost PJ, Ngo K, Barie PS, Hitt J, Kuti JL, Septimus E,
Lawler N, Schilling L, Dorman T: Developing quality measures for sepsis
care in the ICU. Jt Comm J Qual Patient Saf 2007, 33:559–568.
21. Diaz-Martin A, Martinez-Gonzalez ML, Ferrer R, Ortiz-Leyba C, Piacentini E,
Lopez-Pueyo MJ, Martin-Loeches I, Levy MM, Artigas A, Garnacho-Montero J:
Antibiotic prescription patterns in the empiric therapy of severe sepsis:
combination of antimicrobials with different mechanisms of action
reduces mortality. Crit Care 2012, 16:R223.
22. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J,
Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K,
Silva E, Harvey M, Regan S, Angus DC: The surviving sepsis campaign:
results of an international guideline-based performance improvement
program targeting severe sepsis. Intensive Care Med 2010, 36:222–231.
23. Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, Edwards J,
Cho TW, Wittlake WA: Implementation of a bundle of quality indicators
for the early management of severe sepsis and septic shock is
associated with decreased mortality. Crit Care Med 2007, 35:1105–1112.
24. Pestana D, Espinosa E, Sanguesa-Molina JR, Ramos R, Perez-Fernandez E,
Duque M, Martinez-Casanova E: Compliance with a sepsis bundle and its
effect on intensive care unit mortality in surgical septic shock patients.
J Trauma 2010, 69:1282–1287.
25. Schull MJ, Guttmann A, Leaver CA, Vermeulen M, Hatcher CM, Rowe BH,
Zwarenstein M, Anderson GM: Prioritizing performance measurement for
emergency department care: consensus on evidence-based quality of
care indicators. CJEM 2011, 13:300–343.
26. Bochud PY, Bonten M, Marchetti O, Calandra T: Antimicrobial therapy for
patients with severe sepsis and septic shock: an evidence-based review.
Crit Care Med 2004, 32:S495–S512.
27. Hermanides HS, Hulscher ME, Schouten JA, Prins JM, Geerlings SE:
Development of quality indicators for the antibiotic treatment of
complicated urinary tract infections: a first step to measure and improve
care. Clin Infect Dis 2008, 46:703–711.
28. Schouten JA, Hulscher ME, Wollersheim H, Braspennning J, Kullberg BJ, van
der Meer JW, Grol RP: Quality of antibiotic use for lower respiratory tract
infections at hospitals: (how) can we measure it? Clin Infect Dis 2005,
41:450–460.
29. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C: Using and
reporting the Delphi method for selecting healthcare quality indicators:
a systematic review. PLoS One 2011, 6:e20476.
doi:10.1186/1471-2334-14-345
Cite this article as: van den Bosch et al.: Development of quality
indicators for antimicrobial treatment in adults with sepsis. BMC
Infectious Diseases 2014 14:345.
van den Bosch et al. BMC Infectious Diseases 2014, 14:345 Page 10 of 10
http://www.biomedcentral.com/1471-2334/14/345
